CORRECTION OF ANEMIA AT THE PREDIALYSIS STAGE OF CHRONIC RENAL DISEASE IN DIABETES MELLITUS: FROM RESULTS OF CLINICAL TRIALS TO PRACTICAL RECOMMENDATIONS
The wide introduction of erythropoiesis-stimulating agents into clinical use to treat patients with chronic renal disease could reduce the rate of progression of decreased renal function, the frequency of cardiovascular events and improve the quality of life. The results of clinical trials to correct anemia with various epoetins serve as a basis for further development of standards and approaches to treating anemia in patients with chronic renal failure